COMMUNIQUÉS West-GlobeNewswire

TRT UK - What Is TRT and Who Should Take a TRT Test? A Complete UK Guide
21/04/2026
Rising Interest in TRT UK: What Current Medical Guidance Says About Symptoms, Testing, and Access to Treatment Hampshire, England, April 21, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This content is provided for [...]
Moonbuddy Kids Breathing Guidance Under Investigation: Tactile Breathwork Device Claims Get Reviewed
21/04/2026
A 2026 informational overview of Moonbuddy's screen-free calming device for children, slow-paced breathing research context, 4-minute sleep support claims, parasympathetic activation positioning, pricing structure, and [...]
Spectral AI Announces Annual Meeting of Stockholders
20/04/2026
DALLAS, April 20, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate [...]
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
20/04/2026
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
20/04/2026
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected in the second half [...]
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
20/04/2026
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Amwell® to report first quarter 2026 operating results
20/04/2026
BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report first quarter 2026 operating results [...]
MISE À JOUR -- BVI annonce l’obtention du marquage CE au titre du Règlement européen sur les dispositifs médicaux pour Virtuoso®, une toute nouvelle plateforme chirurgicale à double fonction
20/04/2026
Le marquage CE au titre du Règlement européen sur les dispositifs médicaux (MDR de l’UE) a été obtenu pour Virtuoso®, la première plateforme de phaco-vitrectomie à double fonction de BVI, conçue pour offrir un contrôle [...]
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
21/04/2026
Company Marks First Annual Meeting at Historic Perkins Place Office Building as It Prepares to Relocate Its Headquarters from First Horizon Plaza Tower KNOXVILLE, Tenn., April 20, 2026 (GLOBE NEWSWIRE) -- Provectus [...]
FibroBiologics Compliant with All Nasdaq Listing Requirements
20/04/2026
HOUSTON, April 20, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
Regeneron Announces Investor Conference Presentations
20/04/2026
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: • BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 [...]
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/04/2026
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase [...]
Essential Pharma 旗下公司 Renaissance Pharma Limited 用于治疗高危神经母细胞瘤的 Daretabart (hu1418K322A) 获得 FDA 快速通道认定，并通过 IND 审评
21/04/2026
FDA 授予 Daretabart (hu1418K322A) 快速通道认定资格，以解决高危神经母细胞瘤领域存在的重大未满足医疗需求，允许该药物进入加速评审和滚动审评流程 FDA 通过新药临床研究 (IND) 申请后，即可在高危神经母细胞瘤复发及难治性患者中启动 SHINE II/III 期临床试验 Daretabart (hu1418K322A) 第一个商业化规模 GMP 生产批次已顺利完成项目基于 II 期的积极数据， [...]
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
20/04/2026
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel [...]
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
20/04/2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced [...]
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
20/04/2026
LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy
20/04/2026
First‑in‑class DARKFOX‑targeting bispecific T cell engager: ENA101 is designed to selectively recognize the DARKFOX‑A3 peptide presented by HLA‑A*03:01, a highly prevalent HLA allele, enabling precise redirection of T [...]
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering
20/04/2026
WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary [...]

Pages